Investor Relations

Home > Investor Relations > IR Library > Statements of Income and Loss (consolidated)

Statements of Income and Loss (consolidated)

(million yen) 
  FY2015
(2015/4/1-2016/3/31)
FY2016
(2016/4/1-2017/3/31)
Net sales 82,115 84,949
COGS 40,261 45,902
Gross Profit 41,854 39,046
SGA 30,719 32,176
Operating income 11,134 6,869
Non-operating income 1,987 1,307
Interest earned 103 29
Dividends earned 4 4
Subsidy income 538 99
Currency gain 714 551
Reversal of allowance for doubtful accounts 0 272
Other non-operating income 625 350
Non-operating expenses 2,965 760
Interest paid 163 164
Loss on revaluation of currency swaps 2,280 502
Other non-operating expenses 520 92
Ordinary income 10,157 7,417
Extraordinary gain 1 1
Gain on sale of fixed assets 1 1
Extraordinary loss 254 180
Loss on disposal of fixed assets 238 177
Other extraordinary loss 16 3
Net income before income taxes 9,903 7,237
Income taxes 2,247 1,741
Income taxes-deferred 28 79
Total income taxes 2,219 1,661
Income before minority interests 7,684 5,576
Profit attributable to owners of parent 7,684 5,576

Home > Investor Relations > IR Library > Statements of Income and Loss (consolidated)
© Copyright TOWA PHARMACEUTICAL CO.,LTD. All Rights Reserved.